Laboratorios Farmacéuticos ROVI ROVI.MC
Laboratorios Farmacéuticos ROVI is a Spanish pharmaceutical company specializing in the development, manufacturing and sale of prescription drugs, diagnostic products and self-medication, with a business model that combines contract manufacturing (CDMO) with the commercialization of its own brands, including low molecular weight heparin. Laboratorios ROVI shows exceptional growth (earnings +246.7%) with solid financial health (net cash, ND/EBITDA -0.12) and high profitability (ROE 28.65%), although its valuation is not particularly cheap (P/E 16.48) and momentum is weak (19th percentile in 52 weeks).
Detailed metrics
Market and fundamental data as of the analysis date.
Full AI report
Generated automatically from the metrics, the macro context and the company's news.
Laboratorios Farmacéuticos ROVI is a Spanish pharmaceutical company specializing in the development, manufacturing and sale of prescription drugs, diagnostic products and self-medication, with a business model that combines contract manufacturing (CDMO) with the commercialization of its own brands, including low molecular weight heparin. Laboratorios ROVI shows exceptional growth (earnings +246.7%) with solid financial health (net cash, ND/EBITDA -0.12) and high profitability (ROE 28.65%), although its valuation is not particularly cheap (P/E 16.48) and momentum is weak (19th percentile in 52 weeks).
Score by category
| Category | Score |
|---|---|
| Financial health | 7.2 |
| Quality / Moat | 7.3 |
| Valuation | 6.1 |
| Growth | 9.1 |
| Dividend | 5.7 |
| Momentum | 3.6 |
| Risk & Context | 7.8 |
OVERALL SCORE: 7.0/10
Context and risks
Company domiciled in Spain, a country with elevated governance risk according to the assigned profile. A moderate penalty is applied for jurisdictional risk, although the company is not state-owned and its business is global.
News considered in the analysis
- Laboratorios Farmaceuticos Rovi SA (WBO:ROVI) Q2 2026 Earnings Call Highlights: Revenue Growth ... — Resultados del segundo trimestre con crecimiento de ingresos, ya reflejado parcialmente en el precio.
- Global Market Highlights 3 Stocks That May Be Trading Below Fair Value Estimates — Listículo genérico sin información nueva sobre la empresa.
- Laboratorios Farmaceuticos Rovi SA (WBO:ROVI) Q1 2026 Earnings Call Highlights: Navigating ... — Resultados del primer trimestre, ampliamente cubiertos y ya descontados.
- Laboratorios Farmaceuticos Rovi SA (STU:41L) Q4 2025 Earnings Call Highlights: Strategic Growth ... — Resultados del cuarto trimestre de 2025, ya descontados.
- 3 European Stocks Estimated To Be Trading At Discounts Of Up To 46% — Listículo genérico sin información específica accionable.
Verdict: Hold; growth and quality are notable, but weak momentum and average valuation suggest waiting for a better entry point.
Main risk: Concentration in the heparin business and dependence on third-party manufacturing (CDMO) are the most relevant specific risks, along with the jurisdictional risk of Spain.
Other Healthcare companies
Neighbours in the sector ranking, to compare without going back to the index.
See all 1,000+ companies in the index →